Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
US Army
Daiichi Sankyo
Farmers Insurance
Julphar
QuintilesIMS
Cerilliant
Cantor Fitzgerald
Harvard Business School

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,229,630

« Back to Dashboard

Which drugs does patent 7,229,630 protect, and when does it expire?

Patent 7,229,630 protects ORAVERSE and is included in one NDA.

This patent has fifteen patent family members in twelve countries.
Summary for Patent: 7,229,630
Title:Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Abstract:The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
Inventor(s): Chen; Andrew X. (San Diego, CA), Knowles; Julius (Del Mar, CA), Weber; Eckard (San Diego, CA)
Assignee: Novalar Pharmaceuticals, Inc. (DE)
Application Number:10/465,810
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Dosage form; Composition; Device;

Drugs Protected by US Patent 7,229,630

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,229,630

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,569,230 Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof ➤ Sign Up
7,575,757 Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Argus Health
Citi
Baxter
Daiichi Sankyo
McKesson
AstraZeneca
US Department of Justice
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.